Antioxidant disclaimers
This article was originally published in The Tan Sheet
Executive Summary
"FDA has determined that although some scientific evidence suggests that consumption of antioxidant vitamins may reduce the risk of certain forms of cancer, this evidence is limited and not conclusive," reads one acceptable disclaimer crafted to accompany antioxidant health claim, agency tells Durk Pearson et al. in April 6 letter. Washington, D.C. federal court Judge Gladys Kessler directed FDA to permit the claim "consumption of antioxidant vitamins may reduce the risk of certain kinds of cancer" in a Dec. 26 opinion (1"The Tan Sheet" Jan. 6, 2003, p. 15). FDA has developed two other similar disclaimers that companies may use when opting to run the new health claim...
You may also be interested in...
FDA Antioxidants/Cancer Risk Reduction Claim Ban Found Unconstitutional
FDA's rejection of an antioxidants/cancer risk reduction health claim fails to satisfy the conditions that permit a ban of the claim because evidence exists supporting the relationship, according to a Dec. 26 Washington, D.C. federal court opinion
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.